Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):636-50. doi: 10.2174/187152710793361586.
Because G protein-coupled receptors (GPCRs) are numerous, widely expressed and involved in major physiological responses, they represent a relevant therapeutic target for drug discovery, particularly regarding pharmacological treatments of neurological disorders. Among the biological phenomena regulating receptor function, GPCR heteromerization is an important emerging area of interest and investigation. There is increasing evidence showing that heteromerization contributes to the pharmacological heterogeneity of GPCRs by modulating receptor ontogeny, activation and recycling. Although in many cases the physiological relevance of receptor heteromerization has not been fully established, the unique pharmacological and functional properties of heteromers are likely to lead to new strategies in clinical medicine. This review describes the main GPCR heteromers and their implications for major neurological disorders such as Parkinson's disease, schizophrenia and addiction. A better understanding of molecular mechanisms underlying drug interactions related to the targeting of receptor heteromers could provide more specific and efficient therapeutic agents for the treatment of brain diseases.
由于 G 蛋白偶联受体 (GPCR) 数量众多、广泛表达,并参与主要的生理反应,因此它们是药物发现的相关治疗靶点,特别是在治疗神经紊乱的药理学方面。在调节受体功能的生物学现象中,GPCR 异源二聚化是一个备受关注和研究的新兴领域。越来越多的证据表明,异源二聚化通过调节受体的发生、激活和回收,有助于 GPCR 的药理学异质性。尽管在许多情况下,受体异源二聚化的生理相关性尚未完全确立,但异源二聚体的独特药理学和功能特性可能会为临床医学带来新的策略。本文综述了主要的 GPCR 异源二聚体及其在帕金森病、精神分裂症和成瘾等主要神经紊乱中的作用。更好地理解与靶向受体异源二聚体相关的药物相互作用的分子机制,可能为治疗脑部疾病提供更特异和有效的治疗药物。